Medical device change control asks more than whether a revised part still fits. It identifies what changed, which functions and approved evidence the change could affect, who must decide, and which lots may use the new route. A supplier can propose a different tool, resin source or finishing provider; the device owner must evaluate the effect on its product and obligations before calling the change acceptable.
This is a manufacturing-focused guide, not a universal regulatory decision tree. The appropriate review depends on the device, jurisdiction, role of each organization and the scope of the change. The article uses illustrative part changes to show how evidence moves between engineering, quality, procurement and a manufacturing supplier.
The Starting Question: What Is Actually Different?
“Equivalent material” and “same process” are conclusions, not descriptions. Begin with a factual before-and-after record. Identify the approved part revision, material grade and supplier, tool or program, process route, manufacturing site, external provider, acceptance method and packaging where applicable. Then state the proposed difference in terms a reviewer can evaluate.
A change request should also say why it is proposed. A tool has worn, a stock supplier has stopped a grade, a supplier wants more capacity, or a design issue has emerged. The reason does not prove acceptability, but it influences urgency and the alternatives available. A change to fix a known defect needs different scrutiny from a routine capacity adjustment.
The parent medical device manufacturing standards article covers the quality-system setting. Here the focus is the practical decision around one component route: what evidence allows a new configuration to begin without losing control of the old one?
Follow the Change Through Four Effects
For each proposal, ask what it could do to fit, function, safety-related performance and existing verification evidence. A changed surface finish may preserve dimensions while altering coating adhesion or cleaning behavior. A new resin supplier may meet a family designation while changing flow or color. A machining fixture change may improve cycle time but shift the way a datum is held.
| Proposed change | Potentially affected item | Question for the device team | Evidence that may help |
|---|---|---|---|
| New aluminum stock route | Material state or geometry stability | Do approved properties and processing assumptions still apply? | Source specification and representative parts |
| Modified mold insert | Local wall or seal geometry | Does the change touch a critical interface? | Tool record, cavity samples and fit data |
| New coating provider | Thickness and surface behavior | Does the finished state remain within acceptance criteria? | Process comparison and inspection |
| New CNC program | Feature location or edge condition | Are datum and deburring assumptions unchanged? | Program approval and first-part results |
| New assembly adhesive | Bond, cleaning and exposure | What qualification or test evidence is affected? | Material identity and project-specific testing |
The table is not a fixed testing prescription. It helps reveal which technical questions the responsible team must answer. A supplier may propose measurements or trials, but it should not declare that a device-level risk is unchanged without the device owner’s review.
Classify Evidence Before Deciding Tests
List the evidence currently supporting the component: drawing inspection, fit trial, material documentation, process qualification, performance test or assembly evaluation as relevant. Identify which evidence relied on the condition now being changed. A dimensional report may be sufficient for a purely dimensional adjustment, while a polymer or surface change could require different evidence. Do not reflexively repeat every test, but do not skip one because the new part looks similar.
Development samples can be useful if their configuration is clear. Mark the tool, cavity, material lot, finish provider and drawing revision so reviewers know what the sample represents. A favorable prototype result should not be generalized to all production conditions without a rationale.
Para low-volume injection molding, a material or mold adjustment may have implications beyond nominal dimensions.
Para mecanizado CNC, a new setup or stock condition can alter a functional interface even when the same CAD file is used. Those process-specific questions make change control more useful than a one-line approval stamp.
Draw a Clear Line Through Work in Progress
Decide the effective boundary before the supplier releases the new route. Which work orders, material lots or serial numbers were made under the old condition? Which are being held? Which will use the proposed change? A date alone can be misleading if two lines or sites produce parts at the same time.
The organization may need a controlled disposition for inventory already built. A drawing change can leave old parts usable, require reinspection, or make them unsuitable; the answer depends on the specific requirement and evidence. Do not relabel a lot to fit a new revision after the fact. Preserve what it was built to and document the decision about its use.
If the supplier has already implemented a change without notice, the first task is containment and factual reconstruction. Establish the earliest affected lot, locations, quantities and shipped units. Only then can the responsible team assess product implications. Treating it as a paperwork correction before defining the affected population reverses the logic.
Separate Change Control From Two Neighboring Processes
Document control keeps approved instructions and historical versions identifiable. Change control decides whether a proposed alteration is acceptable and what evidence it requires. A perfectly controlled revision can still be technically wrong if nobody assesses the effect of the change.
Corrective action addresses a cause of an existing or potential nonconformance. Some corrective actions result in a controlled change, but the processes are not interchangeable. A supplier may fix a recurring burr by changing a tool path; the team should both investigate the defect and approve the new process route. The existing medical device failure analysis article discusses how to preserve and examine the failed physical part before deciding on a remedy.
El FDA’s QMSR page is the current U.S. starting point for quality-system context, and ISO 14971:2019 provides the medical-device risk-management framework. Qualified personnel should assess whether a given change affects risk files, regulatory submissions or other device-level obligations. No generic supplier blog can make that determination for an unnamed device.
Ask the Supplier for a Decision Package
When discussing a change with Jucheng or another part manufacturer, request a concise package: current and proposed routes, reason, affected part numbers, first affected lot, technical differences, available sample or inspection evidence, and proposed implementation date. The buyer can then identify which internal functions need to review it. A vague “no impact” statement without a comparison is difficult to audit or act on.
The best change-control outcome is not automatically approval or rejection. It is a traceable decision with a defined scope: which configuration is allowed, what evidence supports it, when it starts, and what happens to material already made. That discipline protects both the engineering intent and the practical supply route.
Does every process change require new testing?
Not automatically. The responsible team should assess whether the change could affect a requirement or the evidence supporting it. The rationale for using existing evidence or commissioning new tests should be documented for the specific device and component.
Can the supplier implement first and notify later?
Only if the agreed change process and applicable requirements permit that category of change. For changes requiring prior approval, the supplier should wait for the buyer’s decision and preserve the old configuration until the effective boundary is agreed.
